|
ZNTL | Zentalis Pharmaceuticals, Inc. |
|
|
ZNTL | Zentalis Pharmaceuticals, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 2.55 |
| Leverage | 22.73% |
| Market Cap | $ 99.3m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -148.9m |
| Margin | -560.45% |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers. The company is headquartered in New York, New York.